Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors
← catalyst calendarNCT06132503 · readout in 834 d
Sponsored by Lantern Pharma Inc. (industry) · LTRN — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
110estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-01-03 | actual | When the study began enrolling |
| Primary completion | 2028-11-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-11-30 | estimated | The whole study's end, after follow-up |
| First posted | 2023-11-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Relapsed or Refractory Lymphomas
- Advanced Solid Tumor
Intervention
- Drug: LP-284
Primary outcomes
what the primary-completion date above is the date OFPhase 1a: To evaluate the safety and tolerability of escalating doses of LP-284
measured 12 months
Phase 1a: To determine the maximum tolerated dose (MTD).
measured 12 months
Phase 1a: To determine the recommended Phase 2 dose (RP2D).
measured 12 months
Phase 1b: To obtain preliminary estimates of clinical activity of LP-284
measured 5 years
Permalink · LTRN's whole pipeline · Catalyst calendar · Every registered study · What changed